Fushi Copperweld Rises On Unusually High Volume (FSIN)

NEW YORK ( TheStreet) -- Fushi Copperweld (Nasdaq: FSIN) is trading at unusually high volume Tuesday with 2.2 million shares changing hands. It is currently at 4.1 times its average daily volume and trading up 15 cents (+2.6%) at $5.94 as of 1:15 p.m. ET.

Fushi Copperweld has a market cap of $314.8 million and is part of the industrial goods sector and industrial industry. Shares are down 23% year to date as of the close of trading on Monday.

Fushi Copperweld, Inc., through its subsidiaries, engages in designing, developing, manufacturing, marketing, and distributing copper-clad bimetallic wire products, principally copper-clad aluminum (CCA) and copper-clad steel (CCS). The company has a P/E ratio of 7.8, below the average industrial industry P/E ratio of 13.1 and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Fushi Copperweld as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full Fushi Copperweld Ratings Report.

See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.

Interested in other stocks that are rising on unusually high volume? Get free SMS text alerts sent to you when the action happens by texting HVUP to 95370 or select from multiple alert options.

null

More from Markets

Rewind: Jim Cramer on the Stock Market Rebound, Walmart, Amazon and JCPenney

Rewind: Jim Cramer on the Stock Market Rebound, Walmart, Amazon and JCPenney

Is Nvidia Still Tech's Most Explosive Stock? A Bull and Bear Debate

Is Nvidia Still Tech's Most Explosive Stock? A Bull and Bear Debate

Nvidia Is Tumbling After Beating Earnings but Issuing Light Guidance

Nvidia Is Tumbling After Beating Earnings but Issuing Light Guidance

Teva Notches Win With FDA Approval of Generic EpiPen

Teva Notches Win With FDA Approval of Generic EpiPen

Dow Jumps Nearly 300 Points as U.S. and China to Resume Trade Talks

Dow Jumps Nearly 300 Points as U.S. and China to Resume Trade Talks